Fimbrion Therapeutics (United States)

Recent papers from Fimbrion Therapeutics (United States)

1. An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli confers protection in a mouse model of recurrent urinary tract infectionFrontiers in Immunology · 2026
2. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s diseaseExpert Opinion on Drug Discovery · 2017
3. Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract InfectionsJournal of Medicinal Chemistry · 2016
4. Cover Picture: Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI (ChemMedChem 4/2016)ChemMedChem · 2016
5. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTIChemMedChem · 2016
6. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn’s diseaseExpert Opinion on Therapeutic Patents · 2015